<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178343</url>
  </required_header>
  <id_info>
    <org_study_id>CSNO-2015-MSD01</org_study_id>
    <nct_id>NCT04178343</nct_id>
  </id_info>
  <brief_title>Tomotherapy for Leptomeningeal Metastases</brief_title>
  <official_title>Tomotherapy for Leptomeningeal Metastases: a Single Arm, Single Center, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy
      for leptomeningeal metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, single center, phase II trial to investigate the feasibility and
      toxicity of tomotherapy for leptomeningeal metastases, which are defined as leptomeningeal
      metastases with or without brain metatstases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Actual">October 24, 2018</completion_date>
  <primary_completion_date type="Actual">October 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>the time from radiation to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>up to 1 year</time_frame>
    <description>the time from radiation to leptomeningeal lesion recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intracranial progress free survival</measure>
    <time_frame>up to 1 year</time_frame>
    <description>the time from radiation to leptomeningeal lesion recurrence and/or new brain metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progress free survival rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>the time from radiation to any progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>up to 2 years</time_frame>
    <description>acute and late toxicities</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meningeal Metastases, with or without brain metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>tomotherapy</intervention_name>
    <description>the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;
WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles.
d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF).</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of primary tumor and conformed meningeal metastases
             by enhanced MRI; KPS ≥60,or KPS ≥40 and the limitation of motion is simply caused by
             brain tumor that is adjacent to the motor function areas; Age: 18-75 years old;
             Adequate organ function:WBC≥4.0x109/L Neu ≥ 1.5x109/L Hemoglobin ≥ 110 g/L Platelets
             ≥100 x109/L Total bilirubin ≤ 1.5x ULN AST and ALT ≤ 1.5x ULN BUN and Cr: within the
             normal range.

        Exclusion Criteria:

          -  Other clinically significant diseases (e.g.myocardial infarction within the past 6
             months, severe arrhythmia); unable or unwilling to comply with the study protocol;
             patients who are anticipated in other clinical trials of meningeal metastases;
             pregnant patients or female patients whose HCG is positive; unsuitable to participate
             in study, that in the opinion of the treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianping Xiao, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jianping Xiao</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>tomotherapy</keyword>
  <keyword>leptomeningeal metastases</keyword>
  <keyword>fractionated stereotactic radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

